Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Multispecialty Grand Rounds – Current and Emerging Directions for Pancreatic Cancer
Despite the survival rate advancements in different types of cancer in the last 40 years, the perspective for pancreatic cancer patients has seen no substantial changes. Indeed, the five year survival rate remains around 5%. During this lecture Dr. Eileen O’Reilly will describe the current state of the art for management of advanced pancreatic cancer.
Target Audience
Oncologists, Radiation Oncologists, Hematology Oncologists, Radiation Therapists, General Surgeons, General Practitioners, Obstetricians and Gynecologists, Nurses, Pharmacists, Respiratory Therapists, Patient Navigators and all other interested healthcare professionals.
Learning Objectives
- Describe the current state of the art for management or advanced pancreatic cancer.
- Discuss germline and implementation of somatic profiling and integration into care.
- Assess the emerging direction of treatment of pancreatic cancer.
Eileen M. O’Reilly, M.D.
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobillary Oncology
Co-Director Medical, David M. Rubenstein Center for Pancreas Cacncer
Memorial Sloan Kettering
New York, New York
Eileen M. O’Reilly, M.D., faculty for this educational activity has received research support from Genentech/Roche, Celgene/BMS, BioNTech, BioAlta, AstraZeneca, Acrus, Elicio, Parker Institute and Pertzye. He is also a consultant for Cytomx Therapeutics (DSMB), Rafael Therapeutics, Sobi, Silenseed, Tyme, Seagen, Molecular Templates, Boehringer Ingelheim, BioNTech, Ipsen, Polaris, Merck, IDEAYA, Cend, Astrazeneca, Noxxon, BioSapien, Cend Theraputics, Thetis, Bayer (spouse), Genentech-Roche (spouse), Celgene-BMS (spouse), Eisai (spouse) and Research to Practice. She has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Guilherme Rabinowits, M.D., conference series director, has indicated that he is a consultant with Sanofi and Regeneron.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationship(s) to disclose with ineligible companies*:
*Ineligible companies - Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-680158, by the Florida Boards of Medicine, Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurse Practitioners, Nurses, Pharmacists and Techs and Respiratory Therapists. Baptist Health South Florida CE Broker Provider #50-182.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 General certificate of attendance
- 1.00 Nurse Practitioners
- 1.00 Florida Board of Nursing
- 1.00 Florida Board of Pharmacy
- 1.00 Florida Board of Respiratory Therapy
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
